We are live on ! Find out more
CCM

Camber Capital Management Portfolio holdings

AUM $1.07B
1-Year Est. Return 8.19%
This Fund
S&P 500
This Quarter Est. Return
+0.51%
1 Year Est. Return
-8.19%
3 Year Est. Return
+26.6%
5 Year Est. Return
+54.57%
10 Year Est. Return
+164.72%
AUM
$1.9B
AUM Growth
+$148M
Cap. Flow
+$194M
Cap. Flow %
10.22%
Top 10 Hldgs %
63.78%
Holding
40
New
10
Increased
11
Reduced
7
Closed
5

Top Buys

Rank Stock Value
1
HCA icon
HCA Healthcare
HCA
+$89.7M
2
BHC icon
Bausch Health
BHC
+$77.5M
3
CI icon
Cigna
CI
+$44M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$40.5M
5
OSUR icon
OraSure Technologies
OSUR
+$37.6M

Top Sells

Rank Stock Value
1
GSK icon
GSK
GSK
+$102M
2
ASND icon
Ascendis Pharma A/S
ASND
+$51.8M
3
GKOS icon
Glaukos
GKOS
+$28M
4
SAGE
Sage Therapeutics
SAGE
+$21.8M
5
TBIO
Translate Bio, Inc. Common Stock
TBIO
+$17.9M

Sector Composition

Rank Sector Weight
1 Healthcare 82.31%
2 Technology 11.48%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CHNG
1
DELISTED
Change Healthcare Inc. Common Stock
CHNG
$218M 11.48%
15,000,000
-900,000
-6% -$11.4M
VTRS icon
2
Viatris
VTRS
$20.7B
$178M 9.39%
12,000,000
+1,000,000
+9% +$16M
ALXN
3
DELISTED
Alexion Pharmaceuticals
ALXN
$149M 7.85%
1,300,000
-100,000
-7% -$10.8M
PRGO icon
4
Perrigo
PRGO
$1.43B
$131M 6.9%
2,850,000
+600,000
+27% +$31.4M
UHS icon
5
Universal Health Services
UHS
$9.88B
$123M 6.49%
1,150,000
+150,000
+15% +$16M
ALKS icon
6
Alkermes
ALKS
$8.39B
$120M 6.34%
7,250,000
– –
HCA icon
7
HCA Healthcare
HCA
$85.7B
$90.4M 4.77%
+725,000
New +$89.7M
BHC icon
8
Bausch Health
BHC
$2.25B
$69.9M 3.69%
+4,500,000
New +$77.5M
IRWD icon
9
Ironwood Pharmaceuticals
IRWD
$614M
$65.2M 3.44%
7,250,000
+750,000
+12% +$7.45M
MYGN icon
10
Myriad Genetics
MYGN
$507M
$65.2M 3.44%
5,000,000
+1,000,000
+25% +$12.7M
SRPT icon
11
Sarepta Therapeutics
SRPT
$1.64B
$59.7M 3.15%
425,000
+25,000
+6% +$3.8M
BLUE
12
DELISTED
bluebird bio
BLUE
$59.3M 3.13%
84,920
-13,510
-14% -$10.5M
CI icon
13
Cigna
CI
$76.1B
$42.4M 2.23%
+250,000
New +$44M
COLL icon
14
Collegium Pharmaceutical
COLL
$1.17B
$41.6M 2.2%
2,000,000
– –
NKTR icon
15
Nektar Therapeutics
NKTR
$2.41B
$41.5M 2.19%
166,667
-33,333
-17% -$10.5M
AMAG
16
DELISTED
AMAG Pharmaceuticals
AMAG
$41.3M 2.18%
4,390,000
– –
TEVA icon
17
Teva Pharmaceuticals
TEVA
$41.2B
$40.5M 2.14%
4,500,000
+2,500,000
+125% +$26.4M
CHRS icon
18
Coherus Oncology
CHRS
$227M
$40.3M 2.13%
2,200,000
– –
BKD icon
19
Brookdale Senior Living
BKD
$3.49B
$38.1M 2.01%
15,000,000
– –
OSUR icon
20
OraSure Technologies
OSUR
$273M
$33.5M 1.77%
+2,750,000
New +$37.6M
BMRN icon
21
BioMarin Pharmaceuticals
BMRN
$11.7B
$30.4M 1.61%
+400,000
New +$40.5M
PBYI icon
22
Puma Biotechnology
PBYI
$402M
$25.8M 1.36%
2,555,000
+155,000
+6% +$1.58M
THC icon
23
Tenet Healthcare
THC
$21.8B
$24.5M 1.29%
+1,000,000
New +$25.6M
RDUS
24
DELISTED
Radius Health, Inc.
RDUS
$23.5M 1.24%
2,075,000
+1,700,000
+453% +$21M
TECX
25
Tectonic Therapeutic
TECX
$538M
$23.4M 1.24%
150,000
+37,500
+33% +$7.56M
1
2

Similar funds

PP
PrairieView Partners St. Paul, Minnesota $1.03B AUM 11.4% 1-Year Est. Return
SAF
Smith Anglin Financial Dallas, Texas $1.1B AUM 14.08% 1-Year Est. Return
NRD
Nebula Research & Development New York $1.17B AUM 15.19% 1-Year Est. Return
FC
Forte Capital Rochester, New York $930M AUM 24.11% 1-Year Est. Return
GIM
Grassi Investment Management Santa Clara, California $1.26B AUM 23.4% 1-Year Est. Return
SC
Savoie Capital Chicago, Illinois $805M AUM 19.48% 1-Year Est. Return
BWA
Bordeaux Wealth Advisors Menlo Park, California $781M AUM 26.55% 1-Year Est. Return
CCP
Camelot Capital Partners Laguna Beach, California $686M AUM 163.55% 1-Year Est. Return

Camber Capital Management's Q3 2020 Portfolio in Review

As of Q3 2020, Camber Capital Management held 40 positions worth $1.9B, up 8.5% from $1.75B the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Camber Capital Management deployed $194M of net new capital in Q3 2020, opening 10 new positions and adding to 11 existing holdings. Its largest new stake was HCA Healthcare: 725,000 shares worth $90.4M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 87% a quarter earlier, followed by Technology.

On the sell side, the largest reduction was GSK, an estimated $102M trimmed.

  • Camber Capital Management's largest Q3 2020 buy was HCA Healthcare: 725,000 shares worth $90.4M.
  • Camber Capital Management added most to Perrigo in Q3 2020, an estimated $31.4M increase.
  • Camber Capital Management's biggest Q3 2020 reduction was GSK, cutting an estimated $102M.
  • Camber Capital Management fully exited Ascendis Pharma A/S in Q3 2020, selling an estimated $51.8M.
  • Camber Capital Management's ten largest holdings make up 64% of its $1.9B portfolio in Q3 2020.
  • Camber Capital Management opened 10 new positions and closed 5 in Q3 2020.
  • Camber Capital Management's portfolio value rose 8.5% quarter-over-quarter to $1.9B.

Based on Camber Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.